Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

AbbVie Inc. Reports Strong Q2 Results and Raises Full-Year Guidance


AbbVie Inc. (ABBV) shares gained 1.5% premarket on Thursday following the company’s announcement of stronger-than-expected revenue for the second quarter and an increase in its full-year guidance. The pharmaceutical giant now anticipates adjusted earnings per share for the full-year 2023 to be in the range of $10.90 to $11.10, compared to the previous guidance of $10.57 to $10.97.

Robust Financial Performance

AbbVie posted impressive financial figures, reporting a net income of $2.02 billion, or $1.14 per share, for the quarter. This is a significant improvement compared to the net income of $924 million, or $0.51 per share, in the same period last year. The company’s second quarter revenue reached $13.87 billion, surpassing the $14.58 billion recorded in the previous year and exceeding FactSet’s consensus estimate of $13.54 billion.

Beat Expectations

In addition to strong financial results, AbbVie also outperformed analysts’ expectations in terms of earnings per share. The company reported adjusted earnings per share of $2.91 for the quarter, higher than the $3.37 reported in the same quarter last year and surpassing FactSet’s consensus estimate of $2.83.

Blockbuster Drug Sales

AbbVie’s flagship arthritis drug, Humira, continued to demonstrate its market dominance with sales totaling $4.01 billion in the quarter. This figure exceeded FactSet’s consensus estimate of $3.95 billion and further solidifies Humira’s position as a leading revenue generator for the company.

Market Performance

Despite the challenges faced by the pharmaceutical industry, AbbVie shares have displayed resilience in the market. Year to date, the company’s shares have witnessed a decrease of 12.2%, while the S&P 500 index has experienced a growth of 18.9%.

AbbVie’s robust second quarter results and increased full-year guidance reflect the company’s ability to navigate the changing landscape of the pharmaceutical industry. With Humira’s continued success and a strong financial performance, AbbVie is well-positioned for future growth and success.

Celestica Raises Full-Year Projections After Strong Q2 Earnings

Previous article

EU Investigates Microsoft’s Teams App

Next article

You may also like


Leave a reply

Your email address will not be published.

More in News